Consenso colombiano de expertos sobre recomendaciones basadas en evidencia para el diagnóstico y tratamiento de alteraciones del metabolismo óseo y mineral en pacientes con enfermedad renal crónica
PDF

Palabras clave

Trastorno Mineral y Óseo Asociado a la Enfermedad Renal Crónica, Insuficiencia Renal Crónica, Calidad de Vida, Consenso, Diagnóstico, Terapéutica

Cómo citar

1.
Coronado Daza JA. Consenso colombiano de expertos sobre recomendaciones basadas en evidencia para el diagnóstico y tratamiento de alteraciones del metabolismo óseo y mineral en pacientes con enfermedad renal crónica. Rev. Colomb. Nefrol. [Internet]. 10 de agosto de 2021 [citado 21 de octubre de 2021];8(2):e565. Disponible en: https://revistanefrologia.org/index.php/rcn/article/view/565

Resumen

Introducción: Las alteraciones del metabolismo óseo y mineral asociado a la enfermedad renal crónica (AMOM-ERC) es una de las complicaciones más frecuentes e importantes que afecta la calidad de vida de pacientes con enfermedad renal crónica y sus familias y, además, contribuye al aumento de la morbimortalidad cardiovascular.

Método: A partir de una revisión sistemática de literatura en las bases de datos Embase y Medline vía Pubmed, grupos desarrolladores de evidencia y sociedades científicas, se formularon recomendaciones preliminares por el grupo desarrollador que fueron consultadas a un colectivo experto de nefrología, endocrinología, geriatría, reumatología, medicina interna y cardiología, a través del método Delphi modificado.

Resultados: Se presentan 62 recomendaciones sobre diagnóstico y tratamiento de AMOM-ERC definidas por consenso entre 51 expertos clínicos y el grupo desarrollador. El rango de aprobación de las recomendaciones oscilo entre 80.9% y 100%.

Conclusión: Las recomendaciones presentadas permiten a los expertos clínicos la toma de decisiones clínicas cotidianas basadas en evidencia sobre el diagnóstico y el tratamiento de las alteraciones del metabolismo óseo y mineral en pacientes con enfermedad renal crónica en Colombia.

https://doi.org/10.22265/acnef.8.2.565
PDF

Citas

Schoolwerth AC, Engelgau MM, Hostetter TH. A public health action plan

is needed for chronic kidney disease. Adv Chronic Kidney Dis.

;12(4):418-23.

Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et

al. Global prevalence of chronic kidney disease - A systematic review and

meta-analysis. PLoS One. 2016;11(7):e0158765.

Ministerio de Salud y Protección Social; Ministerio de Hacienda y Crédito

Público. Cuenta de Alto Costo [Internet]. 2020 my. 30 [citado 2021 febr.

. Disponible en: https://cuentadealtocosto.org/site/quienes-somos/

Cuenta de Alto Costo Colombia. Situación de la Enfermedad Renal

Crónica, la Hipertensión Arterial y la Diabetes Mellitus en Colombia,

Cuenta Alto Costo [Internet]. 2019 [citado 2021 Feb 11];1(2322–

:293.

Disponible

en:

https://cuentadealtocosto.org/site/download/situacion-de-la-enfermedad-

renal-cronica-la-hipertension-arterial-y-diabetes-mellitus-en-colombia-

/

Zoccali C, Vanholder R, Massy ZA, Ortiz A, Sarafidis P, Dekker FW, et al.

The systemic nature of CKD. Nat Rev Nephrol. 2017;13(6):344-58.

Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et

al. Definition, evaluation, and classification of renal osteodystrophy: a

position statement from Kidney Disease: Improving Global Outcomes

(KDIGO). Kidney Int. 2006;69(11):1945-53.

Liabeuf S, McCullough K, Young EW, Pisoni R, Zee J, Reichel H, et al.

International variation in the management of mineral bone disorder in

patients with chronic kidney disease: Results from CKDopps. Bone.

;129:115058.

Luján MA, Ramírez JA, Acevedo JM, Gómez S, Cañas JM, Santander D,

et al. Prevalencia de las alteraciones del metabolismo óseo-mineral

asociadas a enfermedad renal crónica no en diálisis. Rev Colomb Nefrol

[Internet]. 2019 mzo 1;6(Artículo de investigación original):17-25.

Disponible en: https://revistanefrologia.org/index.php/rcn/article/view/311

Nakai S, Watanabe Y, Masakane I, Wada A, Shoji T, Hasegawa T, et al.

Overview of regular dialysis treatment in Japan (as of 31 December

. Ther Apher Dial. 2013;17(6):567-611.

Colombia Compra Eficiente [sitio virtual]. Tratamiento de enfermedad

renal crónica. Bogotá: Colombia Compra Eficiente; 2020 [citado 2021

febr. 11]. Disponible en: https://www.colombiacompra.gov.co/tienda-

virtual-del-estado-colombiano/salud/tratamiento-de-enfermedad-renal-

cronica

The Economist. Value-based health in renal care in Latin America.

London:

The

Economist;

Disponible

en:

http://www.eiu.com/graphics/assets/images/public/VBH-in-Renal-Care-in-

Latin-America/Value-based-health-in-renal-care-in-Latin-America.pdf

Belozeroff V, Chertow GM, Graham CN, Dehmel B, Parfrey PS, Briggs

AH. Economic evaluation of cinacalcet in the United States: The EVOLVE

Trial. Value Health. 2015;18(8):1079-87.

Liu ZH, Li G, Zhang L, Chen J, Chen X, Zhao J, et al. Executive

summary: Clinical practice guideline of chronic kidney disease - mineral

and

bone

disorder

(CKD-MBD)

in

China.

Kidney

Dis

(Basel).

;5(4):197-203.

Chen W, Bushinsky DA. Chronic kidney disease: KDIGO CKD–MBD

guideline update: evolution in the face of uncertainty. Nature Reviews

Nephrology. 2017;13(10):600-2.

Forbes A, Gallagher H. Chronic kidney disease in adults: Assessment

and

management.

Clinical

medicine

(Londres,

Inglaterra).

;20(2):128-32.

Malaysian Health Technology Assessment Section. Management of

Chronic

Kidney

Technology

Disease. Putrajaya,

Assessment Section;

Malasia:

Malaysian

Disponible

Health

en:

https://www.moh.gov.my/moh/resources/penerbitan/CPG/CPG

%20Management%20of%20Chronic%20Kidney%20%20Disease

%20(Second%20Edition).pdf

Ministerio de Salud Pública del Ecuador. Prevención, diagnóstico y

tratamiento de la enfermedad renal crónica. Guía de práctica clínica.

Quito: Ministerio de Salud Pública, Dirección Nacional de Normatización-

MSP;

Disponible

en:

https://www.salud.gob.ec/wp-content/uploads/2018/10/guia_prevencion_d

iagnostico_tratamiento_enfermedad_renal_cronica_2018.pdf

De Maré A, Verhulst A, Cavalier E, Delanaye P, Behets GJ, Meijers B, et

al. Clinical inference of serum and bone sclerostin levels in patients with

end-stage kidney disease. J Clin Med. 2019;8(12):2027.

Druck A, Patel D, Bansal V, Hoppensteadt D, Fareed J. Osteopontin

levels in patients with chronic kidney disease stage 5 on hemodialysis

directly

correlate

with

intact

parathyroid

hormone

and

alkaline

phosphatase. Clin Appl Thromb. 2019;25:1-5.

Sprague SM, Bellorin-Font E, Jorgetti V, Carvalho AB, Malluche HH,

Ferreira A, et al. Diagnostic accuracy of bone turnover markers and bone

histology in patients with CKD treated by dialysis. Am J Kidney Dis.

;67(4):559-66.

Aaltonen L, Koivuviita N, Seppänen M, Tong X, Kröger H, Löyttyniemi E,

et al. Correlation between 18F-Sodium Fluoride positron emission

tomography and bone histomorphometry in dialysis patients. Bone.

;134:115267.

Baptista AL, Padilha K, Malagrino PA, Venturini G, Zeri AC, Dos Reis LM,

et al. Potential biomarkers of the turnover, mineralization, and volume

classification: Results using NMR metabolomics in hemodialysis patients.

JBMR plus. 2020;4(7):e10372-e.

Aigner C, Cejka D, Sliber C, Fraunschiel M, Sunder-Plassmann G, Gaggl

M. Oral sodium bicarbonate supplementation does not affect serum

calcification propensity in patients with chronic kidney disease and

chronic metabolic acidosis. Kidney Blood Press Res. 2019;44(2):188-99.

Chen Z, Qureshi AR, Ripsweden J, Wennberg L, Heimburger O, Lindholm

B, et al. Vertebral bone density associates with coronary artery

calcification and is an independent predictor of poor outcome in end-stage

renal disease patients. Bone. 2016;92:50-7.

Liu Y, Lee WC, Cheng BC, Li LC, Lee CH, Chang WX, et al. Association

between the achievement of target range CKD-MBD markers and

mortality in prevalent hemodialysis patients in Taiwan by using the kidney

disease: Improving global outcomes clinical guidelines. Biomed Res Int.

;2016:1523124.

Chadban SJ, Ahn C, Axelrod DA, Foster BJ, Kasiske BL, Kher V, et al.

KDIGO Clinical Practice Guideline on the Evaluation and Management of

Candidates for Kidney Transplantation. Transplantation. 2020;104(4S1

Supl. 1):s11-s103.

Ikizler TA, Burrowes JD, Byham-Gray LD, Campbell KL, Carrero JJ, Chan

W, et al. KDOQI clinical practice guideline for nutrition in CKD: 2020

update. Am J Kidney Dis. 2020;76(3 Supl. 1):s1-s107.

Yadav AK, Kumar V, Kumar V, Banerjee D, Gupta KL, Jha V. The effect

of vitamin D supplementation on bone metabolic markers in chronic

kidney disease. J Bone Miner Res. 2018;33(3):404-9.

Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ, et al.

Phosphate binders for preventing and treating chronic kidney disease-

mineral and bone disorder (CKD-MBD). The Cochrane database of

systematic reviews. 2018;8(8):CD006023-CD.

Sekercioglu N, Thabane L, Díaz-Martínez JP, Nesrallah G, Longo CJ,

Busse JW, et al. Comparative effectiveness of phosphate binders in

patients with chronic kidney disease: A systematic review and network

meta-analysis. PLoS One. 2016;11(6):e0156891.

Sekercioglu N, Angeliki-Veroniki A, Thabane L, Busse JW, Akhtar-

Danesh N, Iorio A, et al. Effects of different phosphate lowering strategies

in patients with CKD on laboratory outcomes: A systematic review and

NMA. PLoS One. 2017;12(3):e0171028.

De Roij-Van Zuijdewijn CL, De Haseth DE, Van Dam B, Bax WA,

Grooteman MPC, Bots ML, et al. Role of albumin assay on calcium levels

and prescription of phosphate binders in chronic hemodialysis patients.

Nephron. 2018;140(3):211-7.

Block GA, Rosenbaum DP, Leonsson-Zachrisson M, Åstrand M,

Johansson S, Knutsson M, et al. Effect of tenapanor on serum phosphate

in patients receiving hemodialysis. J Am Soc Nephrol. 2017;28(6):1933-

Block GA, Rosenbaum DP, Yan A, Chertow GM. Efficacy and safety of

tenapanor in patients with hyperphosphatemia receiving maintenance

hemodialysis: A randomized phase 3 Trial. J Am Soc Nephrol.

;30(4):641-52.

Malhotra R, Katz R, Hoofnagle A, Bostom A, Rifkin DE, McBride R, et al.

The effect of extended release niacin on markers of mineral metabolism

in CKD. Clin J Am Soc Nephrol. 2018;13(1):36-44.

Sekercioglu N, Busse JW, Sekercioglu MF, Agarwal A, Shaikh S, Lopes

LC, et al. Cinacalcet versus standard treatment for chronic kidney

disease:

a

systematic

review

and

meta-analysis.

Ren

Fail.

;38(6):857-74.

Ni LH, Yuan C, Song KY, Wang XC, Chen SJ, Wang LT, et al. Efficacy

and safety of cinacalcet and active vitamin D in the treatment of

secondary hyperparathyroidism in patients with chronic kidney disease: A

network meta-analysis. Ann Transl Med. 2019;7(14):322.

Greeviroj P, Kitrungphaiboon T, Katavetin P, Praditpornsilpa K, Eiam-Ong

S, Jaber BL, et al. Cinacalcet for treatment of chronic kidney disease-

mineral and bone disorder: A meta-analysis of randomized controlled

trials. Nephron. 2018;139(3):197-210.

Palmer SC, Mavridis D, Johnson DW, Tonelli M, Ruospo M, Strippoli

GFM. Comparative effectiveness of calcimimetic agents for secondary

hyperparathyroidism in adults: A systematic review and network meta-

analysis. Am J Kidney Dis. 2020;76(3):321-30.

Floege J, Kubo Y, Floege A, Chertow GM, Parfrey PS. The effect of

cinacalcet on calcific uremic arteriolopathy events in patients receiving

hemodialysis:

The

EVOLVE

Trial.

Clin

J

Am

Soc

Nephrol.

;10(5):800-7.

Cozzolino M, Mangano M, Galassi A, Ciceri P, Messa P, Nigwekar S.

Vitamin K in chronic kidney disease. Nutrients. 2019;11(1):168.

Udomkarnjananun S, Kongnatthasate K, Praditpornsilpa K, Eiam-Ong S,

Jaber BL, Susantitaphong P. Treatment of calciphylaxis in CKD:

A systematic review and meta-analysis. Kidney international reports.

;4(2):231-44.

Peng T, Zhuo L, Wang Y, Jun M, Li G, Wang L, et al. Systematic review

of sodium thiosulfate in treating calciphylaxis in chronic kidney disease

patients. Nephrology. 2018;23(7):669-75.

Coyne DW, Singh HN, Smith WT, Giuseppi AC, Connarn JN, Sherman

ML, et al. Sotatercept safety and effects on hemoglobin, bone, and

vascular calcification. Kidney Int Reports. 2019;4(11):1585-97.

Brandenburg VM, Sinha S, Torregrosa JV, Garg R, Miller S, Canals AZ,

et al. Improvement in wound healing, pain, and quality of life after 12

weeks of SNF472 treatment: a phase 2 open-label study of patients with

calciphylaxis. J Nephrol. 2019;32(5):811-21.

Ape trii M, Goldsmith D, Nistor I, Siriopol D, Voroneanu L, Scripcariu D, et

al. Impact of surgical parathyroidectomy on chronic kidney disease-

mineral and bone disorder (CKD-MBD) - A systematic review and meta-

analysis. PLoS One. 2017;12(11):e0187025.

Palmer SC, Chung EY, McGregor DO, Bachmann F, Strippoli GF.

Interventions for preventing bone disease in kidney transplant recipients.

The cochrane database of systematic reviews. 2019;10(10):CD005015-

CD.

Araujo M, Ramalho JAM, Elias RM, Jorgetti V, Nahas W, Custodio M, et

al. Persistent hyperparathyroidism as a risk factor for long-term graft

failure: the need to discuss indication for parathyroidectomy. Surgery.

;163(5):1144-50.

Nanmoku K, Shinzato T, Kubo T, Shimizu T, Takachi Y. Effects of

denosumab on hypercalcemia and bone mineral density loss in kidney

transplant recipients. Clin Nephrol. 2019;(0301-0430):1-9.

Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.

Descargas

Los datos de descargas todavía no están disponibles.